The aim of this study is to develop a comprehensive understanding of Nateglinide (NGL) and Voglibose (VGB), focusing on their pharmaceutical formulation, analytical methods, and therapeutic applications in diabetes management with their different mode of action of the human body. The primary objective is to address critical gaps in current knowledge by exploring the solubility profiles, stability characteristics, and compatibility of NGL and VGB to develop the combined dosage forms. This research aims to develop robust stability-indicating methods for the simultaneous estimation of NGL and VGB, ensuring accuracy and specificity in pharmaceutical formulations. In this paper, mainly focus on the estimation of both of the drug by High Performance Liquid Chromatography technology (mainly RP-HPLC) with estimating the stability of drugs by performing the food degradation analysis like acid hydrolysis, alkaline hydrolysis, oxidative degradation and Thermal degradation. Also performing the recovery studies of the both of the drug with their different percentage level like 80%, 100%, and 120%. By achieving these objectives, the research aims to contribute to advancements in diabetes treatment, pharmaceutical sciences, and patient care outcomes through evidence-based innovations in drug development and formulation technology with formulating the combined drug that are ensuring the stability of the components present in the formulated drug.